NCT05257174

Brief Summary

Fatigue is a common feature in patients with rheumatic conditions. Fatigue can lead to a decline in physical function, self-confidence, cognitive status, and work performance and significantly impact the quality of life. While pain and inflammation of arthritis can be well controlled nowadays attributed to the advances in anti-rheumatic medications, fatigue remains a challenge. Even with proper therapies for arthritis, the prevalence of severe fatigue is more than 30%, which is a significant burden to both physicians and patients. However, there is no regimen to alleviate fatigue among patients with inflammatory arthritis. Finding a way to combat fatigue will significantly help improve patients' physical and mental state and family society. To investigate the efficacy of Jing Si Herbal Tea Liquid Packets on fatigue in patients with inflammatory arthritis, the investigators propose a two-year research project to recruit approximately 150 patients with fatigue and inflammatory arthritis, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. This project is designed as a randomized, double-blind, placebo-controlled study. The recruited patients will be randomized to receive Jing Si Herbal Tea Liquid Packets or a matching placebo in combination with the background regular anti-rheumatic therapy. The severity of fatigue will be obtained by questionnaire. Clinical parameters, including demographic data and disease activities, will be collected during each visit.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jun 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 28, 2022

Completed
28 days until next milestone

First Posted

Study publicly available on registry

February 25, 2022

Completed
4 months until next milestone

Study Start

First participant enrolled

June 15, 2022

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2024

Completed
Last Updated

July 27, 2023

Status Verified

July 1, 2023

Enrollment Period

1.5 years

First QC Date

January 28, 2022

Last Update Submit

July 25, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in level of fatigue [Time Frame: 4, 8, 12 weeks after Jing Si Herbal Tea Liquid Packets]

    Fatigue assessment measured by the functional assessment of chronic illness Therapy- Fatigue (FACIT- F) (0-52; higher score=less fatigue)

    Change of fatigue level every 4 weeks until 12 weeks after Jing Si Herbal Tea Liquid Packets

Secondary Outcomes (1)

  • Change in disease activity of inflammatory arthritis [Time Frame: 4, 8, 12 weeks after Jing Si Herbal Tea Liquid Packets]

    Change of disease activity every 4 weeks until 12 weeks after Jing Si Herbal Tea Liquid Packets

Study Arms (2)

Jing Si Herbal Tea LIQUID PACKETS

EXPERIMENTAL

one packet oral twice daily for three months

Dietary Supplement: Jing Si Herbal Tea LIQUID PACKETS

Placebo

PLACEBO COMPARATOR

one packet oral twice daily for three months

Dietary Supplement: Placebo

Interventions

intake Jing Si Herbal Tea LIQUID PACKETS twice daily for three months

Jing Si Herbal Tea LIQUID PACKETS
PlaceboDIETARY_SUPPLEMENT

intake Placebo twice daily for three months

Placebo

Eligibility Criteria

Age20 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • inflammatory arthritis, any of the following diagnosis
  • Rheumatoid arthritis, based on ACR (American College of Rheumatology) classification criteria
  • Ankylosing spondylitis, based on modified New York Criteria
  • Psoriatic arthritis, based on 2006 CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria

You may not qualify if:

  • active infection or chronic infection
  • uncontrolled disease status of inflammatory arthritis
  • unwilling to take herbal tea
  • with difficulty for return visits

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

Hualien City, 970, Taiwan

Location

Related Publications (2)

  • Overman CL, Kool MB, Da Silva JA, Geenen R. The prevalence of severe fatigue in rheumatic diseases: an international study. Clin Rheumatol. 2016 Feb;35(2):409-15. doi: 10.1007/s10067-015-3035-6. Epub 2015 Aug 15.

    PMID: 26272057BACKGROUND
  • Esbensen BA, Stallknecht SE, Madsen ME, Hagelund L, Pilgaard T. Correlations of fatigue in Danish patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis. PLoS One. 2020 Aug 3;15(8):e0237117. doi: 10.1371/journal.pone.0237117. eCollection 2020.

    PMID: 32745130BACKGROUND

MeSH Terms

Conditions

ArthritisArthritis, RheumatoidSpondylitis, AnkylosingArthritis, PsoriaticFatigue

Condition Hierarchy (Ancestors)

Joint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System DiseasesAxial SpondyloarthritisSpondylarthropathiesSpondylarthritisSpondylitisSpinal DiseasesBone DiseasesAnkylosisPsoriasisSkin Diseases, PapulosquamousSkin DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Kuei-Ying Su, MD,PhD

    Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 28, 2022

First Posted

February 25, 2022

Study Start

June 15, 2022

Primary Completion

December 31, 2023

Study Completion

June 1, 2024

Last Updated

July 27, 2023

Record last verified: 2023-07

Data Sharing

IPD Sharing
Will share

Data obtained through this study may be provided to qualified researchers with academic interest in fatigue among patients with inflammatory arthritis. Data or samples shared will be coded, with no PHI (protected health information) included. Approval of the request and execution of all applicable agreements (i.e. a material transfer agreement) are prerequisites to the sharing of data with the requesting party.

Shared Documents
STUDY PROTOCOL
Time Frame
Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis.

Locations